Type Whole antibody Target MUC1 CAS Number 943976-23-6 | Source Humanized (from mouse) ATC code none ChemSpider none | |
Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.
The drug was developed by Immunomedics, Inc.
In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival.
References
Yttrium (90Y) clivatuzumab tetraxetan Wikipedia(Text) CC BY-SA